Abstract: A power measurement apparatus configured to measure power consumed at a load, the apparatus includes a magnetic film module, an adjuster, a measurement resistance, and a voltage detector. The magnetic film module is arranged so that a longitudinal direction of the magnetic film module is parallel to current flowing in the load. The adjuster is configured to adjust a pass-frequency and a phase of a voltage at one terminal of the magnetic film module. The measurement resistance is serial-connected to the magnetic film module. The voltage detector is configured to detect a voltage between both terminals of the magnetic film module.

Abstract: In order to provide (i) a medical composition that has a strong angiogenic effect, has low invasiveness to a body of a patient, and is easy to administer to a living subject and (ii) a medical kit using a medical composition, the medical composition includes: a carrier in a particle form, the carrier having (a) a support made from a bioabsorbable polymer and (b) a surface layer made from hydroxyapatite and provided on the support; and cells provided on a surface of the carrier.

Abstract: The present invention relates to a composition for enhancing collagen production, for enhancing elastin production and/or for enhancing keratinocyte migration, including sesaminol as an active component. The present invention also relates to a method for enhancing collagen production, for enhancing elastin production and/or for enhancing keratinocyte migration, including administering the composition.

Abstract: The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX.

Abstract: Provided are an improved double-stranded nucleic acid molecule involved in gene expression control mediated by a gene silencing mechanism, a method of producing the molecule, and a pharmaceutical composition comprising the double-stranded nucleic acid molecule. The double-stranded nucleic acid molecule for gene expression control comprises an antisense strand having a length of 18 to 28 nucleotides and a sense strand including a complementary moiety composed of a sequence sufficiently complementary to the antisense strand and a protruding single-stranded 5?-end moiety having a length of 2 to 100 nucleotides. The sense strand and the antisense strand form base pairs via the complementary moiety. The method produces such a double-stranded nucleic acid molecule, and the pharmaceutical composition contains such a double-stranded nucleic acid molecule as an active ingredient.

Abstract: An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R4 is lower alkyl, R3 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

Abstract: This clamp-type ammeter has a flexible substrate of which an inner wall is configured to be able to deform into a substantially cylindrical shape. The clamp-type ammeter has a plurality of magnetic sensor elements disposed at the inner wall of the flexible substrate. The clamp-type ammeter has a tube of which one end is connected to the flexible substrate. The clamp-type ammeter has an operation unit that is connected to the other end of the tube and that can operate the deformation of the flexible substrate.

Abstract: Provided are a treatment method for an organic halogen compound, which allows the organic halogen compound to be efficiently decomposed without a large-scale treatment device or high operating cost, and a catalyst to be used for the treatment method. In the treatment method, an organic halogen compound is subjected to decomposition treatment by heating the organic halogen compound at a temperature of from 100° C. to 200° C. in the presence of a catalyst formed of copper oxide and hydrogen peroxide, to subject the organic halogen compound to a hydrothermal oxidation reaction utilizing a Fenton method.

Abstract: An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R4 is lower alkyl, R3 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

Abstract: The purpose of the present invention is to develop and provide a nucleic acid molecule that can specifically and efficiently inhibit the activity of a target RNAi molecule and can be produced safely at a low cost. Provided is a nucleic acid molecule for inhibiting the activity of a target RNAi molecule. The nucleic acid molecule comprises a single-stranded nucleic acid moiety that contains one unmodified DNA region composed of a nucleotide sequence completely or sufficiently complementary to a nucleotide sequence of a functional strand having the activity in the target RNAi molecule and a double-stranded nucleic acid moiety to be linked to at least one of the 5?-end and the 3?-end of the single-stranded nucleic acid moiety.

Abstract: In order to provide a 3V level non-aqueous electrolyte secondary battery with a flat voltage and excellent cycle life at a high rate with low cost, the present invention provides a positive electrode represented by the formula: Li2±?[Me]4O8?x, wherein 0??<0.4, 0?x<2, and Me is a transition metal containing Mn and at least one selected from the group consisting of Ni, Cr, Fe, Co and Cu, said active material exhibiting topotactic two-phase reactions during charge and discharge.

Abstract: An object of the present invention is to provide a medicament and method for treating lissencephaly patients. The present invention provides a lissencephaly therapeutic or preventive agent comprising a compound represented by the general formula (I): wherein R1 is lower alkyl substituted with lower alkoxy, lower alkyl substituted with a heterocyclic group, a heterocyclic group, or a group represented by the formula (IIa): wherein R4 is lower alkyl, R5 is lower alkylene, and m is an integer of 1 to 6; R2 is lower alkyl optionally substituted with phenyl; and R3 is lower alkyl optionally substituted with halogen, lower alkoxy, or phenyl; condensed polycyclic hydrocarbon; or hydrogen.

Abstract: Suitable adhesive properties and dismantling properties can be obtained, and an interface between an adherent/an adhesive layer or an adhesive layer/a substrate can be suitably dismantlable by the easily dismantlable adhesive composition including an acrylate polymer including a (meth)acrylate monomer having a carboxyl precursor group, 2-ethyl hexyl acrylate, and a monomer having a polar group as a monomer, and an acid catalyst or an acid generator.

Abstract: Suitable adhesive properties and dismantling properties can be obtained, and an interface between an adherent/an adhesive layer or an adhesive layer/a substrate can be suitably dismantlable by the easily dismantlable adhesive composition including an acrylate polymer including a (meth)acrylate monomer having a carboxyl precursor group, 2-ethyl hexyl acrylate, and a monomer having a polar group as a monomer, and an acid catalyst or an acid generator.

Abstract: An easily dismantlable adhesive composition is provided containing: an acrylic polymer; and either an acid catalyst or an acid generator, the acrylic polymer containing: as monomer components, a carboxyl-precursor-group-containing-(meth)acrylate monomer; an n-butyl acrylate; and a polar-group-containing monomer, the content of the polar-group-containing monomer being 5 to 30% by mass, relative to the total mass of the monomer components composing the acrylic polymer, makes it possible to realize favorable adhesion- and dismantling properties and favorable delamination at an interface between an adherend and a substrate or an interface between an adhesive agent layer and an adherend when dismantled.

Abstract: The heat medium transport paths are arranged between the first building and the second building and transport heat media that transport heat energy. A temperature distribution acquisition means acquires the temperature distribution of the heat media that have temperatures being different from each other in the heat medium transport paths and that are sequentially transported in a state of having a predetermined length in the transport direction in the heat medium transport paths. A control means receives a load request of an air conditioner of the first building, and when a heat medium having the heat energy that satisfies the load request received reaches the first building, based on the temperature distribution acquired by the temperature distribution acquisition means, the control means causes the air conditioner of the first building to take out the heat energy from the heat medium reached.

Abstract: Provided are a treatment method for an organic halogen compound, which allows the organic halogen compound to be efficiently decomposed without a large-scale treatment device or high operating cost, and a catalyst to be used for the treatment method. In the treatment method, an organic halogen compound is subjected to decomposition treatment by heating the organic halogen compound at a temperature of from 100° C. to 200° C. in the presence of a catalyst formed of copper oxide and hydrogen peroxide, to subject the organic halogen compound to a hydrothermal oxidation reaction utilizing a Fenton method.

Abstract: [SUMMARY] [PURPOSE] The invention provides a novel therapeutic agent or prophylactic agent for cognitive disorders. [SOLUTION MEANS] The invention provides an antibody that participates in antigen-antibody reaction specifically with tau protein that has been phosphorylated in the vicinity of Ser413 of SEQ ID NO: 1, and a therapeutic agent or prophylactic agent for cognitive disorders comprising as an active ingredient a peptide that has been phosphorylated in the vicinity of Ser413.

Abstract: There is a limit on the miniaturization of electric leakage detecting apparatuses including a ring-shaped magnetic material. Any thicker electric wires increase the size of the ring-shaped magnetic material. Additionally, it is difficult to place the ring-shaped magnetic material around the electric wires that have already been placed. In light of the foregoing, an electric leakage apparatus is provided. The electric leakage detecting apparatus is to be installed on a pair of power source lines connecting a power source and a load, and includes: a pair of holders configured to hold the power source lines, respectively; a fixing means configured to fix the holders at a predetermined interval; a pair of magnetic elements each placed on each of the holders while being parallel to the power source lines; a detecting means configured to detect a difference between magneto-resistance effects of the magnetic elements; and a driving means configured to feed a drive current to the magnetic elements.

Abstract: An encrypted-traffic discrimination device includes an input interface, a flow discrimination section, a data accumulation section, a selective data calculation section, a calculation result determination section, and an output interface. The flow discrimination section discriminates the input traffic into separate flows based on at least a transmission origin address and a transmission destination address. The data accumulation section accumulates characteristic amount data of the traffic for each of the separate flows. The selective data calculation section executes an evaluation computation utilizing specific data from the characteristic amount data. The calculation result determination section that, based on a calculated evaluation computation value, executes threshold value determination to determine whether or not the traffic is encrypted, and, if the traffic is determined to be encrypted, which encryption format the traffic is encrypted with.